1406P Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib
| Autor: | Wells, J.C., Ho, C., Melosky, B., Laskin, J., Wang, Y., Mullin, M., Sun, S. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S805-S805 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|